GE Builds Personalized Cancer Diagnostics Portfolio With Clarient Purchase

GE Healthcare’s $580 million acquisition of Clarient Inc. will accelerate the health care conglomerate’s expansion into cancer diagnostics and therapy selection tools while enhancing its existing diagnostics and life sciences offerings, the company says.